DelveInsight’s “Frontotemporal Dementia (FTD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Frontotemporal Dementia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Frontotemporal Dementia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Frontotemporal Dementia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Frontotemporal Dementia (FTD): An Overview
FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (FTD): behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders.
FTD occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. FTD encompasses clinical disorders that include changes in behavior, language, executive control, and often motor symptoms.
FTD is considered young-onset dementia, occurring mainly between the ages of 45 to 65, and is the most common dementia in those under 60 years of age. In most cases, the cause of a frontotemporal disorder is unknown. In about 15–40% of people, a genetic (hereditary) cause can be identified. Individuals with a family history of frontotemporal disorders are more likely to have a congenital form of the disease than those without it.
Currently, there is no cure for FTD and no way to slow down or prevent the disease. However, the symptoms can be managed by, medications such as antidepressants, antipsychotics used as an off-label treatment to manage behavior symptoms, speech therapy, and occupational therapies used to manage symptoms associated with language and movement respectively.
Frontotemporal Dementia Market Key Facts
Total Frontotemporal Dementia diagnosed prevalent cases in the 7MM were found to be 128,570 in 2021, which might increase by the end of 2032. These cases are expected to increase at a CAGR of 0.3% during the study period (2019–2032).
Among 7MM, the United States has the highest Frontotemporal Dementia prevalent cases with 58,960 cases in 2021.
On the basis of type-specific diagnosed prevalent cases of Frontotemporal Dementia, bvFTD accounted for the highest number of cases in 2021 with 35,846 cases in the United States.
Among the European countries, Germany had the highest Frontotemporal Dementia diagnosed prevalent population with 14,856 cases, followed by France with 11,983 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
Japan accounted for 11,845 diagnosed prevalent cases of Frontotemporal Dementia in the year 2021.
Some of the major pharma giants in the Frontotemporal Dementia therapeutics market include Alector Inc., Transposon Therapeutics, Oncolys BioPharma, Denali Therapeutics Inc., Passage Bio, Inc., Prevail Therapeutics, Wave Life Sciences, others.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Frontotemporal Dementia pipeline therapies. It also thoroughly assesses the Frontotemporal Dementia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Frontotemporal Dementia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Frontotemporal Dementia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Frontotemporal Dementia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Frontotemporal Dementia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Frontotemporal Dementia Epidemiology, Segmented as –
Diagnosed Prevalent Cases of Frontotemporal Dementia (FTD)
Type-specific Diagnosed Prevalent Cases of Frontotemporal Dementia (FTD)
Gene-specific Diagnosed Prevalent Cases of Frontotemporal Dementia (FTD)
Frontotemporal Dementia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Frontotemporal Dementia market or expected to be launched during the study period. The analysis covers the Frontotemporal Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Frontotemporal Dementia drugs based on their sale and market share.
The report also covers the Frontotemporal Dementia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Frontotemporal Dementia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Frontotemporal Dementia Market Will Evolve and Grow by 2032 @
Frontotemporal Dementia Therapeutics Analysis
Currently, there are no FDA, EMA, or PMDA (Pharmaceuticals and Medical Devices Agency) approved disease-modifying therapies for the management of FTD. The current treatment strategies mainly rely upon the off-label use of medications for symptomatic management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials.
Many FTD symptoms of specific cognitive and behavioral features can be treated, for which, both pharmacological and behavioral interventions are available. In FTD, non-pharmacological interventions should be considered first, with medications considered in conjunction with such treatments. The FTD drugs market is categorized based on drug class such as Selective serotonin reuptake inhibitors (Citalopram, Fluoxetine), Antipsychotic Agents, Cholinesterase Inhibitors (donepezil, rivastigmine, and galantamine), NMDA receptor antagonists (Memantine), and Benzodiazepine Antianxiety Drugs.
Several major pharma and biotech companies developing therapies for Frontotemporal Dementia. Currently, Deerland Probiotics & Enzymes is leading the therapeutics market with its Frontotemporal Dementia drug candidates in the most advanced stage of clinical development.
Frontotemporal Dementia Companies Actively Working in the Therapeutics Market Include
WaVe Life Sciences
And Many Others
Emerging and Marketed Frontotemporal Dementia Therapies Covered in the Report Include:
PR 006: Prevail Therapeutics
PBFT-02: Passage Bio
WVE-004: WaVe life Sciences
EXO-050: Coya Therapeutics
And Many Others
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Frontotemporal Dementia Competitive Intelligence Analysis
4. Frontotemporal Dementia Market Overview at a Glance
5. Frontotemporal Dementia Disease Background and Overview
6. Frontotemporal Dementia Patient Journey
7. Frontotemporal Dementia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Frontotemporal Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Frontotemporal Dementia Unmet Needs
10. Key Endpoints of Frontotemporal Dementia Treatment
11. Frontotemporal Dementia Marketed Therapies
12. Frontotemporal Dementia Emerging Drugs and Latest Therapeutic Advances
13. Frontotemporal Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Frontotemporal Dementia Market Outlook (In US, EU5, and Japan)
16. Frontotemporal Dementia Companies Active in the Market
17. Frontotemporal Dementia Access and Reimbursement Overview
18. KOL Views on the Frontotemporal Dementia Market
19. Frontotemporal Dementia Market Drivers
20. Frontotemporal Dementia Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Bacterial Vaginosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Bacterial Vaginosis market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States